Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $25.60

Astria Therapeutics, Inc. (NASDAQ:ATXS) has earned an average rating of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $25.60.

ATXS has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Monday, January 13th. Oppenheimer increased their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th.

Astria Therapeutics Stock Down 3.2 %

Shares of NASDAQ ATXS opened at $7.50 on Monday. Astria Therapeutics has a twelve month low of $6.95 and a twelve month high of $16.90. The company has a market cap of $423.23 million, a PE ratio of -3.59 and a beta of 0.70. The business’s 50 day moving average price is $9.43 and its two-hundred day moving average price is $10.62.

Institutional Investors Weigh In On Astria Therapeutics

A number of institutional investors have recently modified their holdings of the business. Quest Partners LLC increased its position in Astria Therapeutics by 3,310.6% during the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 3,112 shares during the period. PDT Partners LLC bought a new stake in shares of Astria Therapeutics in the third quarter valued at approximately $140,000. SG Americas Securities LLC bought a new stake in shares of Astria Therapeutics in the third quarter valued at approximately $155,000. Hsbc Holdings PLC acquired a new stake in Astria Therapeutics during the second quarter worth approximately $171,000. Finally, Intech Investment Management LLC bought a new position in Astria Therapeutics during the 3rd quarter worth $228,000. Institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.